Table 8.

Parameters Varied in Probabilistic and Deterministic Sensitivity Analyses

Parameter	Range Tested	Distribution
Starting Age	Range in REDUCE-IT trial	Normal
Proportion Males/Females	± 25%	Beta α= 3.828 β= 1.518
Statin Intensity	± 25%	Dirichlet α= 0.627 β= 0.309
Percentage of Ezetimibe Use	± 25%	Beta α= 14.911 β= 217.830
Percentage of PCI vs CABG	± 25%	Beta α= 3.250 β= 1.083
Revascularization rates in Canada vs United States	± 25%	Beta α= 9.937 β= 17.923
HR Primary Endpoint - First event	SE	Beta Individual parameter for each endpoint
Individual Component of the Primary Endpoint – First event	± 25%	Beta Individual parameter for each endpoint
Individual Component of the Primary Endpoint – Subsequent event	± 25%	Beta Individual parameter for each endpoint
Mortality Multiplier	SE	Gamma Individual parameter for each endpoint
Survival Parameters (Shape, Scale)	SE	Normal
Annual Drug Cost for Standard of Care	Lower and Higher Statin	Gamma α= 1.099 β= 135.064
Health Care Cost	SE	Gamma Individual parameter for each cost
Monitoring and Follow-up Frequency	Clinical Expert Range	Gamma Individual parameter for each item
Monitoring and Follow-up Frequency	Difference between General Practitioner and Cardiologist	Gamma
Adverse Event Incidence	± 25%	Beta Individual parameter for each AE
Adverse event costs	SE	Gamma Individual parameter for each AE
Utility	SE	Beta Individual parameter for each health state

Abbreviations: CABG, coronary artery bypass grafting; HR, hazard ratio; PCI, percutaneous coronary intervention; SE, standard error.